FTC Says Ivax Misconstrues Hatch-Waxman Rules

Law360, New York (April 8, 2005, 12:00 AM EDT) -- The U.S. Food and Drug Administration should reject Ivax Pharmaceutical Inc.’s "flawed" petition for a 180-day marketing exclusivity period for its generic version of Merck & Co.’s cholesterol-lowering drug Zocor, the Federal Trade Commission argued in a brief filed with the court this week.

Ivax submitted an abbreviated new drug application (ANDA) for generic Zocor in 2000 and was entitled to exclusivity under two of Merck & Co.'s patent claims as mandated by the Hatch-Waxman Act.

Under the Hatch-Waxman Act, Congress afforded the first filer of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.